Table 1.
Clinical characteristics of gastric cancer patients according to p53 associated lncRNAs.
| id | futime | fustat | age | gender | grade | stage | T |
|---|---|---|---|---|---|---|---|
| M | 238.411(0.390) | −1.163(0.246) | 54.815(0.150) | 1.467(0.144) | 0.848(0.654) | 160.226 (1.638e-34) | 14.592(0.002) |
| N | 223.52(0.661) | −2.231(0.027) | 35.767(0.836) | 0.54(0.590) | 4.754(0.093) | 158.099 (4.714e-34) | 23.625(2.992e-05) |
| GAS5 | 240.878(0.348) | −0.399(0.690) | 45.535(0.450) | 0.636(0.526) | 1.269(0.530) | 10.033(0.018) | 1.91(0.591) |
| MIR4435-2HG | 241.32(0.340) | −2.289(0.023) | 51.075(0.247) | −1.152(0.250) | 3.526(0.172) | 6.744(0.081) | 5.542(0.136) |
| MALAT1 | 239.743(0.367) | 1.238(0.217) | 35.085(0.856) | −0.375(0.708) | 5.038(0.081) | 15.262(0.002) | 18.328(3.763e-04) |
| PVT1 | 231.538(0.515) | 1.626(0.105) | 68.316(0.014) | 0.968(0.335) | 0.291(0.864) | 1.633(0.652) | 12.253(0.007) |
| RAD51-AS1 | 244.3(0.293) | −0.118(0.906) | 47.671(0.365) | −0.567(0.571) | 3.766(0.152) | 2.011(0.570) | 12.011(0.007) |
| TGFB2-AS1 | 231.1(0.523) | −1.104(0.271) | 43.958(0.516) | −0.808(0.420) | 6.291(0.043) | 0.979(0.806) | 11.358(0.010) |
| CASC9 | 237.237(0.411) | 1.396(0.164) | 46.499(0.410) | −0.051(0.959) | 0.694(0.707) | 0.778(0.855) | 2.738(0.434) |
| XIST | 240.347(0.357) | 1.76(0.080) | 54.626(0.154) | 11.624(5.959e-21) | 0.49(0.783) | 0.687(0.876) | 6.334(0.096) |
| riskScore | 242.676(0.318) | −4.146(5.178e-05) | 58.626(0.084) | −4.198(3.739e-05) | 1.58(0.454) | 9.774(0.021) | 15.515(0.001) |